A cost-consequence analysis of different screening procedures in Alzheimer’s Disease: Results from the MOPEAD project
Manuscript Number:
21-0303R2
Author(s):
Mark Belger, Mercè Boada, Jaka Bon, Annette Dumas, Miren Gurruchaga Telleria, Laura Jamilis, Frank Jessen, Gunilla Johansson, Milica G. Kramberger, Adrián Rodrigo Salas, Octavio Rodríguez-Gómez, Lena Sannemann, Malou Stoekenbroek, Sergi Valero, Lisa Vermunt, Pieter Jelle Visser, Lisa Waterink, Anders Wimo, Bengt Winblad, Marissa Zwan
Disclosures
Mark Belger
Equity:
I am a shareholder at Eli Lilly
Sponsors:
I am an employee and minor shareholder of Eli Lilly